TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial

Por Bartlett, J M S, Nielsen, T O, Gao, D, Gelmon, K A, Quintayo, M A, Starczynski, J, Han, L, Burnell, M J, Levine, M N, Chen, B E, Shepherd, L E, Chapman, J W
Publicado no Br J Cancer (2015)

Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials

Por Yerushalmi, R., Dong, B., Chapman, J. W., Goss, P. E., Pollak, M. N., Burnell, M. J., Levine, M. N., Bramwell, V. H. C., Pritchard, K. I., Whelan, T. J., Ingle, J. N., Shepherd, L. E., Parulekar, W. R., Han, L., Ding, K., Gelmon, K. A.
Publicado no Ann Oncol (2017)